On June 12th, Cutia Therapeutics (Cutia), a joint venture invested by C&D Emerging Investment and its partners, was successfully listed on the Main Board of the Hong Kong Stock Exchange under the stock code 2487.HK.
C&D Emerging Investment constantly focuses on investment opportunities in three key sectors: health care, advanced manufacturing, and TMT consumption. Through its direct investment business, the company has achieved remarkable success, with a total of 34 portfolio companies successfully listed. In the future, C&D Emerging Investment will continue to assist excellent fund managers and entrepreneurs in their growth, while also contributing to the steady development of the country's emerging industries.